



Financial Tear Sheet

Corporate Profile

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

Stock Information

MYOK (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$45.15
Change (%)	▼ 2.05 (4.34%)
Volume	314,103
52 Week Low	\$10.55
Market Cap	\$1,421,760,497
Rolling EPS	-0.67
PE Ratio	0
Shares Outstanding	31,489,712

Data as of 09/22/17 4:00 p.m. ET



Recent Press Releases

09/18/17

MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America's 21st Annual Scientific Meeting

08/30/17

MyoKardia to Present at Two Upcoming Investor Conferences in September

08/14/17

MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

Upcoming Events



















Wednesday, September 27, 2017 8:00 a.m. ET

MyoKardia Inc at the 2017 Cantor Fitzgerald Global Healthcare Conference

SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads
09/14/17	8-K	Report of unscheduled material events or corporate event	Current Reports	   
09/12/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
09/12/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
09/07/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
08/24/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   
08/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	   

08/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5				
08/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5				
08/10/17	SC 13G/A	An amendment to the SC 13G filing	Other				
08/09/17	4	Statement of changes in beneficial ownership of securities	3,4,5				

<< First | Previous | Next | Last >>

Corporate Governance

Tassos Gianakakos Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer Vice President, Business Development and Business Operations

Ingrid Boyes Senior Vice President, Human Resources

Steven Chan Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell Senior Vice President of Drug Discovery

Iris Roth, Ph.D. Vice President, Program Team Leader